GlassScriptPhysician profile
Sarah B Maples
NPI 1598182479
$4,047.95
in general payments reported to CMS, 2019-2025
40 companies · $833 in 2025
The $833 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $855 · 2020: $263 · 2021: $516 · 2022: $389 · 2023: $806 · 2024: $386 · 2025: $833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,025.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,024.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $723.53 | 2019-2025 | |
| Novo Nordisk INC | $393.29 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $313.41 | 2021-2025 | |
| Glaxosmithkline, LLC. | $294.23 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $244.92 | 2019-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $224.88 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $194.20 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $148.91 | 2019-2023 | Farxiga |
| Teva Pharmaceuticals USA, INC. | $142.18 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $132.41 | 2021-2024 | |
| Corcept Therapeutics | $130.76 | 2023 | Korlym |
| Edwards Lifesciences Corporation | $119.88 | 2025 | Pascal, Sapien 3 Ultra Resilia |
| Astellas Pharma US INC | $115.98 | 2025 | Veozah |
| Amgen INC. | $91.84 | 2020-2025 | Krystexxa, Repatha, Otezla |
| Amarin Pharma, INC. | $66.76 | 2019-2021 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Maples listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.